Allogenic and autologous anti-CD7 CAR-T cell therapies in relapsed or refractory T-cell malignancies

Chimeric antigen receptor-T (CAR-T) therapy remains to be investigated in T-cell malignancies. CD7 is an ideal target for T-cell malignancies but is also expressed on normal T cells, which may cause CAR-T cell fratricide. Donor-derived anti-CD7 CAR-T cells using endoplasmic reticulum retention have...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Yinqiang, Li, Chenggong, Du, Mengyi, Jiang, Huiwen, Luo, Wenjing, Tang, Lu, Kang, Yun, Xu, Jia, Wu, Zhuolin, Wang, Xindi, Huang, Zhongpei, Zhang, Yanlei, Wu, Di, Chang, Alex H., Hu, Yu, Mei, Heng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10125858/
https://www.ncbi.nlm.nih.gov/pubmed/37095094
http://dx.doi.org/10.1038/s41408-023-00822-w

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10125858/
https://www.ncbi.nlm.nih.gov/pubmed/37095094
http://dx.doi.org/10.1038/s41408-023-00822-w

Ejemplares similares